Evidence map›Paper›PMID 33424145›Full record

ReviewIndian journal of clinical biochemistry : IJCB2021

Review on COVID-19 Etiopathogenesis, Clinical Presentation and Treatment Available with Emphasis on ACE2.

Himani Rathi, Vishakha Burman, Sudip Kumar Datta, Satya Vati Rana, Anissa Atif Mirza, Sarama Saha, Raman Kumar, Manisha Naithani

Open access · bronzeAbstract readReview
In one paragraph

Review in Indian journal of clinical biochemistry : IJCB, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Cosolvent and Dynamic Effects in Binding Pocket Search by Docking Simulations.Journal of chemical information and modeling · 2021
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Himani RathiDepartment of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand India.
Vishakha BurmanDepartment of Biotechnology, SVBP University of Agriculture and Technology, Meerut, Uttar Pradesh India.
Sudip Kumar DattaDepartment of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi, India.
Satya Vati RanaDepartment of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand India.
Anissa Atif MirzaDepartment of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand India.
Sarama SahaDepartment of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand India.
Raman KumarDepartment of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand India.
Manisha NaithaniDepartment of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand India.
All India Institute of Medical Sciences RishikeshAll India Institute of Medical Sciences · INSardar Vallabhbhai Patel University of Agriculture & Technology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In December 2019, Wuhan city in the Hubei province of China reported for the first time a cluster of patients infected with a novel coronavirus, since then there has been an outburst of this disease across the globe affecting millions of human inhabitants. Severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2), is a member of beta coronavirus family which upon exposure caused a highly infectious disease called novel coronavirus disease-2019 (COVID-19). COVID-19, a probably bat originated disease was declared by World Health Organization (WHO) as a global pandemic in March 2020. Since then, despite rigorous global containment and quarantine efforts, the disease has affected nearly 56,261,952 laboratory confirmed human population and caused deaths of over 1,349,506 lives worldwide. Virus passes in majority through respiratory droplets and then enters lung epithelial cells by binding to angiotensin converting enzyme 2 (ACE2) receptor and there it undergoes replication and targeting host cells causing severe pathogenesis. Majority of human population exposed to SARS-CoV-2 having fully functional immune system undergo asymptomatic infection while 5-10% are symptomatic and only 1-2% are critically affected and requires ventilation support. Older people or people with co-morbidities are severely affected by COVID-19. These categories of patients also display cytokine storm due to dysfunctional immune response which brutally destroys the affected organs and may lead to death in some. Real time PCR is still considered as standard method of diagnosis along with other serology, radiological and biochemical investigations. Till date, no specific validated medication is available for the treatment of COVID-19 patients. Thus, this review provides detailed knowledge about the different landscapes of disease incidence, etiopathogenesis, involvement of various organs, diagnostic criteria's and treatment guidelines followed for management of COVID-19 infection since its inception. In conclusion, extensive research to recognize novel pathways and their cross talk to combat this virus in precarious settings is our future positive hope.

Indexed as

Clinical trialsEtiopathogenesisNovel coronavirus disease-2019 (COVID-19)Severe acute respiratory syndrome coronavirus-2 (SARS-COV-2)

Identifiers

PMID33424145
PMCPMC7778574
OpenAlexW3118381828

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.